Australia's most trusted
source of pharma news
Thursday, 20 March 2025
Posted 5 July 2024 AM
Nine innovative meds, ranging from cancer treatments to bird flu vaccines could hit the Australian market in 2025 after being accepted for review by the TGA in May.
Astellas Pharma has filed avacincaptaf pegol for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.